Compounds > machilin a
Page last updated: 2024-11-12

machilin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

machilin A: stimulates osteoblast differentiation; isolated from Myristica fragrans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10359012
CHEMBL ID261367
MeSH IDM0534148

Synonyms (6)

Synonym
CHEMBL261367
machilin a
5-[(2s,3r)-4-(1,3-benzodioxol-5-yl)-2,3-dimethyl-butyl]-1,3-benzodioxole
5-[(2r,3s)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-1,3-benzodioxole
5,5'-[(2r,3s)-2,3-dimethylbutane-1,4-diyl]bis(2h-1,3-benzodioxole)
9g9 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID433939Cytotoxicity against human A375 cells assessed as inhibition of DNA synthesis in at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433937Cytotoxicity against human HepG2 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433940Cytotoxicity against human A375 cells assessed as inhibition of RNA synthesis at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433938Cytotoxicity against human A375 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID323986Proliferative potency in human MCF7 BUS cells assessed as induction of maximal cell proliferation relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID323983Estrogenic potency in human MCF7 BUS cells assessed as drug level inducing maximal cell proliferation2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID323985Proliferative effect in human MCF7 BUS cells assessed as increase in cell number relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID323984Proliferative effect in human MCF7 BUS cells assessed as ratio of increase in cell number in drug treated to control2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID433936Cytotoxicity against human MCF7 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433941Cytotoxicity against human A375 cells assessed as inhibition of protein synthesis at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433935Cytotoxicity against human HT-29 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		2.0510catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.0510antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
sb 203580
[no description available]		2.0510imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.7730
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.0510actinomycinmutagen
terameprocol
[no description available]		2.0510lignan
licarin b
licarin B: neolignan; RN given for (2S-(2alpha,3beta,5(E)))-isomer; isolated from seeds of Myristica fragrans; structure in first source		2.0410
macelignan
macelignan: an NSAID with antioxidant, free radical scavenging, and neuroprotective activities; structure in first source		2.4620lignan
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0410
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0410
Malignant Melanoma
[description not available]		02.0510
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0510